With Open Enrollment Season in full swing, we’ve been fielding a lot of questions about why health insurance premiums have been going up so much this year. Between rising premiums, deductibles, co-pays and co-insurance, even lots of folks who have had a reliably affordable employer-based group health insurance plan year after year, have had to . . . → Read More: Why Are My Health Insurance Premiums Going Up? Study Shows Healthcare CEOs Earn Top Pay
It’s a cautious thumbs-up from a Medicare coverage advisory committee for Dendreon’s prostate cancer drug Provenge. The committee, made up of health industry experts, doctors and researchers, found enough evidence to support the use of Provenge for late-stage prostate-cancer patients whose disease has metastasized, but not for those prostate cancer patients whose cancer hasn’t progressed.
The recommendation is . . . → Read More: Medicare Committee Recommends Payment for Provenge for Some Prostate Cancer Patients